Recent ENVB News
- Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 • Business Wire • 05/19/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:15:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 12:05:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 12:00:31 PM
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 • Business Wire • 05/15/2026 12:00:00 PM
- Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders • Business Wire • 05/13/2026 12:00:00 PM
- Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model • Business Wire • 05/05/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:02:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 08:00:31 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/29/2026 09:27:14 PM
- Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors • PR Newswire (US) • 04/28/2026 11:33:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/23/2026 08:30:47 PM
- Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum • Business Wire • 04/21/2026 12:00:00 PM
- Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules • Business Wire • 04/17/2026 10:28:00 PM
- Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules • Business Wire • 04/17/2026 12:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/14/2026 08:06:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/14/2026 08:05:16 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 09:05:48 PM
- Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates • Business Wire • 03/31/2026 12:00:00 PM
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 • Business Wire • 03/27/2026 09:40:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 09:27:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:25:41 PM
